Compositions and methods for preventing T cell depletion
By overexpressing FOXO1 in CAR-T cells and combining chimeric antigen receptors to simulate antigen exposure, the problem of loss of function of CAR-T cells under chronic stimulation was solved, and enhanced memory cell formation and durability were achieved, significantly improving the The ability to control tumors.
Patent Information
- Application Number
- CN202380036116.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-25
- Filing Date
- 2023-04-25
- Publication Date
- 2024-12-06
AI Technical Summary
CAR-T cells gradually lose their effect function under chronic antigen stimulation, resulting in reduced efficacy. Existing checkpoint inhibitors do not respond to most patients, and CAR T cells lack memory T cells, affecting long-term survival and recurrent problems.
By introducing exogenous nucleic acids encoding FOXO1, T cells overexpress FOXO1, bind to chimeric antigen receptors (CARs), mimic antigen exposure in vitro and in vivo, reduce inhibitory receptor expression, enhance memory-like phenotype and function, Unstable domains regulate FOXO1 expression and promote memory cell formation and durability.
Significantly enhance the killing ability and durability of CAR-T cells, reduce exhaustion characteristics, improve tumor control ability, prolong mouse survival, and demonstrate stronger anti-tumor effects in in vivo and in vitro models.
Smart Images

Figure CN119095606A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 334,462, filed on April 25, 2022, the contents of which are incorporated herein by reference in their entirety. Technical Field
[0003] The present disclosure relates to compositions comprising T cells modified to overexpress FOXO1 and methods of using the same.
[0004] Sequence Listing Statement
[0005] The contents of the electronic sequence listing entitled "STDU2-39531-601_SQL.xml" (size: 4,128 bytes; and creation date: April 24, 2023) are incorporated herein by reference in its entirety. Background Art
[0006] The efficacy of chimeric antigen receptor (CAR) T cells is limited by T cell exhaustion, whereby chronic CAR signaling induces a gradual loss of function. Checkpoint inhibitors usually target exhaustion. However, most patients do not respond to these agents, and the efficacy of combined use with CAR T cells is not shown in clinical trials. Memory T cells are long-lived and highly proliferative progenitor cells that produce effector T cells when encountering antigens again, which are essential for anti-tumor immune responses and are related to the response to checkpoint blockade and adoptive T cell therapy. The CAR-T cells infused into patients lack a large number of memory T cells. Poor persistence and relapse of CAR-T in patients are associated with defects in the formation of memory CAR-T cells. Summary of the invention
[0007] Provided herein are compositions comprising isolated T cells comprising an exogenous nucleic acid encoding forkhead box protein O1 (FOXO1). In some embodiments, FOXO1 is wild-type FOXO1. In some embodiments, FOXO1 is a fully or partially nuclear localized FOXO1. In some embodiments, FOXO1 is constitutively expressed by an exogenous nucleic acid. In some embodiments, FOXO1 is fused to a motif (e.g., a degradation determinant, an instability domain, etc.) that regulates expression levels or enhances intracellular degradation.
[0008] In some embodiments, the isolated T cells remain functional under conditions in which unmodified T cells exhibit exhaustion.
[0009] In some embodiments, the isolated T cell further includes a nucleic acid encoding a recombinant receptor. In some embodiments, the recombinant receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR). In some embodiments, the recombinant receptor is specific for a tumor antigen.
[0010] In some embodiments, FOXO1 and the engineered receptor are encoded by separate nucleic acids. In some embodiments, FOXO1 and the engineered receptor are encoded by a single nucleic acid. In some embodiments, FOXO1 and the engineered receptor are expressed under different promoters.
[0011] In some embodiments, the isolated T cells are from a biological sample of a subject. In some embodiments, the T cells are isolated from a tumor sample. In some embodiments, the T cells are expanded ex vivo.
[0012] In some embodiments, the composition further comprises at least one therapeutic agent.
[0013] Also provided herein are methods of treating a disease or disorder in a subject, comprising administering to a subject having the disease or disorder an effective amount of a disclosed composition. In some embodiments, the T cells are autologous to the subject. In some embodiments, FOXO1 is overexpressed in the T cells prior to exposure to the antigen. In some embodiments, the method further comprises administering to the patient one or more chemotherapeutic agents.
[0014] In some embodiments, the disease or disorder comprises an infectious disease or cancer. In some embodiments, the cancer is a solid tumor. In some embodiments, the recombinant receptor is specific for cancer.
[0015] In some embodiments, administration reduces the number of cancer cells in a patient. In some embodiments, administration reduces and / or eliminates tumor burden in a patient. In some embodiments, administration shows enhanced cancer treatment compared to administration of unmodified T cells. In some embodiments, administration results in lower expression of inhibitory receptors in a subject compared to administration of unmodified T cells.
[0016] Additionally provided herein are methods for preventing exhaustion of engineered T cells, the methods comprising introducing into the engineered T cells a nucleic acid that overexpresses FOXO1. In some embodiments, the nucleic acid promotes constitutive expression of FOXO1 by the nucleic acid.
[0017] In some embodiments, FOXO1 is wild-type FOXO1. In some embodiments, FOXO1 is fully or partially nuclear-localized FOXO1. In some embodiments, FOXO1 is fused to a motif (e.g., a degron, an instability domain, etc.) that regulates expression levels or enhances intracellular degradation.
[0018] In some embodiments, the engineered T cell comprises a nucleic acid encoding a recombinant receptor. In some embodiments, the recombinant receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR). In some embodiments, the recombinant receptor is specific for a tumor antigen. In some embodiments, FOXO1 is overexpressed prior to exposure to an antigen.
[0019] In some embodiments, FOXO1 and the engineered receptor are encoded by separate nucleic acids. In some embodiments, FOXO1 and the engineered receptor are encoded by a single nucleic acid. In some embodiments, FOXO1 and the engineered receptor are expressed under different promoters.
[0020] In some embodiments, the method further comprises administering the T cells to a subject in need thereof. In some embodiments, the subject has cancer.
[0021] Other aspects and embodiments of the present disclosure will become apparent from the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figures 1A-1C Shown is the use of destabilization domain (DD) modified CARs to explore depletion reversal. Figure 1A It is a schematic diagram of the DD-CAR adjustable platform. Figure 1B is the dose-titration curve of GD2-28z-DD CAR. Figure 1C Schematic diagram of the HA-28z-DD in vitro model of CAR T cell depletion. CAR surface density was normalized between groups before functional assays at D15 (Weber et al., Science, 2021).
[0023] Figure 2A-2C Figure 2 shows the expansion, viability ( Figure 2A ) and phenotypic analysis of CAR+ cell surface and intracellular proteins by flow cytometry ( Figure 2B and 2C ). Figure 2A is a graph showing that FOXOi dose-dependently inhibits CAR-T cell expansion and viability during ex vivo expansion. Figure 2B It was shown that FOXO1i dose-dependently reduced the expression levels of FOXO1 target genes and increased the expression of T cell effector / exhaustion markers. Figure 2CIt is shown that FOXO1i dose-dependently reduces the frequency of memory-like (CD45RA+ / CD62L+) CAR-T cell population and increases the frequency of effector-like population (CD45RA- / CD62L-). 1 representative donor from n=2 donors.
[0024] Figure 3A Schematic diagram of an exemplary co-transduction method disclosed herein. In short, human T cells are first transduced with a retrovirus encoding CAR. After 24 hours, CAR-T cells are then transduced with a separate retrovirus encoding a separate truncated NGFR (negative control) or a bicistronic vector containing a transcription factor plus a truncated NGFR. Other iterations of this method include reverse order (TF first, then CAR), and transduction in which each virus is mixed at a ratio of 1: 1. Figure 3B Shown are intracellular flow cytometry of CD19.28z CAR-T cells co-transduced to express an ectopic TF. 1 representative donor from n=5 independent donors.
[0025] Figure 4A Phenotypic analysis by flow cytometry at day 15 after activation of CD19.BBz CAR-T cells + / - TF is shown. Control NGFR cells and cells ectopically expressing TF showed similar expression levels of exhaustion and differentiation markers. Similar data were obtained for CD19.28z CAR-T cells. Data represent n=5 independent donors. CD19.28z CAR-T cells were unstimulated (Unstim) or cross-linked with anti-FMC63 idiotypic antibody plus cross-linked goat anti-mouse secondary antibody for 5 hours in the presence of monensin and anti-CD107a antibodies on day 15 (Stim) as a surrogate readout of degranulation. Cells were then processed for flow cytometry and stained with an additional antibody against the early activation marker CD69 ( Figure 4B ). The data show that CD69 and CD107a expression is comparable in stimulated NGFR+ or NGFR- CAR-T cells. Similar data were obtained for CD19.BBz CAR-T cells. n = 1 donor.
[0026] Figures 5A-5D is co-transduced CD19.28z ( Figure 5A and 5B ) or CD19.BBz( Figure 5C and 5D) CAR-T cells that were subjected to Miltenyi magnetic purification to isolate NGFR+ cells (using anti-NGFR-biotin antibody and streptavidin magnetic beads) on day 11 after activation. On day 15, CAR+NGFR+ cells were then co-cultured with Nalm6 cells engineered to express GFP and luciferase (Nalm6) at a 1:1 ratio ( Figure 5A and 5C ) or 1:4( Figure 5B and 5D ) E:T ratio co-culture. By ELISA ( Figure 5A and 5C ) to determine cytokine secretion and by Incucyte assay ( Figure 5B and 5D ) Cytotoxicity was determined. At these E:T ratios, there were no detectable differences in cytokine secretion and killing between conditions. 1 representative donor from n=2 donors.
[0027] Figure 6A-6B Intracellular flow cytometry of CAR+ / NGFR+ / CD4+CD19.BBz CAR-T cells is shown, indicating that ectopic expression of FOXO1-WT and nuclear restricted FOXO1-3A increases the expression of endogenous LEF1 and TCF1. Similar data were obtained for CD4+ subsets as well as CD19.28z CAR-T cells. 1 representative donor from n=2 donors.
[0028] Figures 7A-7C Intracellular flow cytometry of CAR+ / NGFR+ / CD8+CD19.BBz CAR-T cells that were unstimulated (Unstim) or stimulated (Stim) using the method described in the description of Figure 5 is shown. Stimulated FOXO1-WT cells showed enhanced expression of endogenous LEF1, TCF1, T-bet, and Blimp-1 compared to NGFR control cells. Similar data were obtained for CD4+ subsets as well as CD19.28z CAR-T cells. n = 1 donor.
[0029] Fig. 8AFlow cytometry of the phenotype of co-transduced CD19.BBz CAR-T cells that were challenged 0, 1, or 3 times with Nalm6 at a 1:1 ratio and analyzed 7 days after stimulation is shown. CAR+ / NGFR+ / CD8+FOXO1-WT and FOXO1-3A CAR-T cells maintained FOXO1 target gene expression and memory-like cell subsets (CD62L+ / IL-7R+) after multiple rounds of tumor challenge, in contrast to CAR-T cells expressing NGFR or TCF1 alone, which rapidly lost this memory-like subset. Similar data were obtained for CD4+ subsets and CD19.28z CAR-T cells (not shown). Representative donors from n=3 independent donors. Figure 8B and 8C Figure 2 is a graph of data from co-transduced CD19.28z or CD19.BBz CAR-T cells purified on NGFR+ cells and subsequently co-cultured with Nalm6 at an E:T ratio of 1:16, showing that FOXO1-WT CAR-T cells maintained tumor killing to a greater extent than FOXO1-3A or NGFR control cells. Fig.8D is a graph of NGFR+CD19.28z CAR-T cells co-cultured with Nalm6 at an E:T ratio of 1:4 and counted 5 days after tumor challenge. The data show enhanced expansion of FOXO1-WT cells. n=1 donor.
[0030] Fig. 9A and 9B Figure 14: Flow cytometric phenotyping of CAR+ / NGFR+ / CD8+HA.28z CAR-T cells at day 14, showing decreased expression of exhaustion markers and increased expression of memory markers in FOXO1-WT and FOXO1-3A CAR-T cells compared with NGFR control cells. Similar results were obtained for the CD4+ subset. Fig. 9C Figure 1 is a picture of NGFR+ purified HA.28z CAR-T cells co-cultured with 143B osteosarcoma cells engineered to express GFP and luciferase (143B) at an E:T ratio of 1:8. Incucyte data showed enhanced tumor killing in FOXO1-WT cells compared to FOXO1-3A and NGFR cells. Fig.9D and 9E It is from 143B( Fig.9D ) or Nalm6( Fig.9E) engineered to express GD2 (N6 GD2), showing enhanced IL-2 secretion by NGFR+ purified HA.28z FOXO1-WT cells compared to FOXO1-3A and NGFR cells, and enhanced IFNy secretion compared to NGFR cells. Representative donor from n=2 donors.
[0031] Fig. 10A Figure 2 is the flow cytometry result of human T cells transduced to express DD-FOXO1-WT, which were co-cultured with trimethoprim (TMP) at different concentrations for 48 hours, which increased intracellular FOXO1-WT expression in a dose-dependent manner. n = 1 donor. Fig. 10B is a graph of NGFR+ purified HA.28z CAR-T cells cultured in the presence of TMP from day 4-15 or on day 14-15 and then co-cultured with N6-GD2 at a 1:1 E:T ratio in the presence of TMP on day 15. ELISA data of co-culture supernatants showed increased IL-2 secretion in CAR-T cells cultured with TMP from day 4-15, but not in CAR-T cells cultured with TMP from day 14-15. Representative donor from n=2 donors.
[0032] Fig.11A Figure 1 is a graph of Seahorse assay results of co-transduced CD19.28z or HA.28z CAR-T cells purified on NGFR+ cells. Data show that basal ECAR is reduced and spare respiratory capacity (SRC) is enhanced in FOXO1-WT and FOXO1-3A cells compared with NGFR control cells. n = 1 donor. Statistical significance was determined using one-way ANOVA and Dunnett's multiple comparison test. **p<0.01; ****p<0.0001. Fig. 11B and 11C Figure 2 Flow cytometry data of co-transduced CD19.28z CAR-T cells stained with mitotracker green. Cells were gated for CAR+ / NGFR+ / CD8+. Data show enhanced mitochondrial mass in FOXO1-WT and FOXO1-3A cells compared to NGFR at baseline and after stimulation with Nalm6 (no GFRP or luciferase) at a 1:1 ratio for 24 hours. Similar data were observed in the CD4+ subset. Representative donor from n=2 donors.
[0033] Fig. 12ACompared with mice treated with untransduced (blank control), NGFR or TCF1-expressing T cells, mice treated with FOXO1-WT and FOXO1-3A CAR-T cells showed enhanced tumor control and survival. Nalm6 cells (1e6) were transplanted into NSG mice and infused with a subtherapeutic dose of 0.1e6 CD19.28z+ / NGFR+T cells 7 days after transplantation. Data show 5-11 mice per group, from n=2 donors (TCF1 conditions were derived from only 1 donor). Statistical data were determined using the log-rank Mantel-Cox test. Fig. 12B is a graph showing tumor enhancement in mice treated with FOXO1-WT and FOXO1-3A CAR-T cells compared to mice treated with T cells expressing NGFR or TCF1. Nalm6 (1e6) cells were transplanted into NSG mice and 1e6 CD19.BBz+ / NGFR+ T cells were infused 7 days after transplantation. Data show 3-5 mice per group from n=1 donor. Fig. 12C In, use Fig. 12B Same experimental setup as in , except cells were not purified on the NGFR+ subset and only single transduced CD19.BBz or co-transduced CD19.BBz+FOXO1-WT cells were compared. FOXO1-WT cells again showed enhanced tumor control at days 39-45 post-transplantation. Data represent 9-10 mice per group from n=2 donors. Fig.12D HA.28z CAR-T cells or cells co-transduced with FOXO1-WT were cultured ex vivo for 15 days. 1e6CAR+T cells (without NGFR+ purification) were then infused into NSG mice 7 days after Nalm6-GD2 transplantation. FOXO1-WT cells showed tumor control at day 52 after transplantation. Data represent 5 mice per group from n=1 donor. Statistical significance was determined using one-way ANOVA and Dunnett's multiple comparison test. *p<0.05; **p<0.01
[0034] Fig.13A is a schematic diagram of an exemplary in vivo model. In brief, 1e6 Nalm6 cells were transplanted into NSG mice and a therapeutic dose of CD19.28z+ / NGFR+T cells were infused 7 days later. 21 days after CAR-T infusion, mice were challenged again with 10e6 Nalm6 cells. Peripheral blood was harvested 7 days after CAR-T infusion and every 7 days thereafter. Fig. 13B is a graph of Nalm6 bioluminescence data showing equivalent and nearly complete tumor control in each treatment group of mice. Fig. 13C and 13DFigure 2 is flow cytometry data showing similar CAR and NGFR levels observed on circulating human CD45+ T cells at day 14 after CAR-T infusion. Representative mice from each group are shown.
[0035] Figures 14A-14C Shows the source Fig.13A Data from the experiments outlined in . Fig.14A and 14B is a graph of total circulating CAR-T cell levels determined using flow cytometry and quantibright beads. FOXO1-WT cells showed the most robust expansion in response to primary tumor challenge and re-challenge. 3-7 mice / group from n=1 donor. Fig. 14C In the study, mice were re-challenged with 10e6 CD19+ or CD19neg Nalm6 on day 21 after CAR-T infusion. Only the FOXO1-WT treated group responded to the re-challenge again, resulting in a significant survival advantage. 1-2 mice / CD19neg group and 2-5 mice / CD19+ group. One-way ANOVA and Dunnett's multiple comparison test ( Fig.14A ) and the log-rank Mantel-Cox test ( Fig. 14C ) to determine statistical significance. *p<0.05; **p<0.01; ***p<0.001
[0036] Fig.15A and 15B Display data from Fig.13A Experiments outlined in . Graphs show the frequencies of circulating CD4 and CD8 CAR-T cells at each time point as determined by flow cytometry. FOXO1-WT exhibited the most robust CD8 expansion (day 7) compared to the NGFR, TCF1, and FOXO1-3A groups, while both FOXO1-WT and FOXO1-3A exhibited enhanced CD8 persistence compared to the NGFR and TCF1 groups (days 15 and 21). n=3-7 mice / group from n=1 donor. Statistical significance was determined using one-way ANOVA and Dunnett's multiple comparison test. ***p<0.001; ****p<0.0001
[0037] Fig.16A is a graph showing enhanced IFNy secretion and cytotoxicity in response to 143B tumor cells compared to controls of single (Her2.28z) or co-transduced (Her2.28z+FOXO1-WT) CAR-T cells purified on NGFR+ cells using magnetic bead selection. n=1 donor. Fig. 16BFigure 2 is flow cytometry of co-transduced Her2.BBz CAR-T cells, showing enhanced expression of memory markers by NGFR+ (e.g., FOXO1-WT) cells relative to NGFR- or Her2.BBz single-transduced cells. Fig. 16C is a graph showing enhanced IL-2 secretion and cytotoxicity in response to 143B tumor cells compared to controls of single (Her2.BBz) or co-transduced (Her2.BBz+FOXO1-WT) CAR-T cells purified on NGFR+ cells using magnetic bead selection. n=1 donor. Fig.16D and 16E In the study, NSG mice were transplanted with 1e6 143B cells and infused with 5e6 Her2.BBz or Her2.BBz+FOXO1-WT CAR-T cells (approximately 50% of which were NGFR+). Caliper measurements of tumor volume showed enhanced tumor control in mice treated with FOXO1-WT cells compared to mice treated with Her2.BBz control cells. Data represent 4-5 mice / group from n=1 donor. Statistical significance was determined using one-way ANOVA and Dunnett's multiple comparison test. *p<0.05.
[0038] Fig.17 Transcription factor motif analysis of resting CAR-T cells was shown, demonstrating enhanced accessibility of memory-associated transcription factor motifs compared to exhausted AlwaysON or non-exhausted AlwaysOFF controls (Weber et al. 2021Science).
[0039] Figures 18A-18C Ectopic FOXO1-WT was shown to reduce depletion when constitutively expressed in a bicistronic vector also containing the CAR sequence. Fig.18A Schematic diagram of CAR T cells retrotransduced with HA.28z CAR alone (HA-28z) or a bicistronic vector containing both FOXO1-WT and HA-28z CAR (FOXO1-HA-28z). Fig.18B Results showed that FOXO1-HA-28z CAR-T cells displayed increased intracellular FOXO1, increased memory markers (CD62L and CD45RA), and decreased exhaustion markers (LAG-3 and TIM-3) compared with cells expressing HA-28z alone. Fig.18C is a graph showing that FOXO1-HA-28z CAR-T cells exhibit enhanced cytokine secretion in response to tumor stimulation.
[0040] Figures 19A-19DFigure 2 shows the characterization of CD19.BBζCAR T cells overexpressing FOXO1-WT, FOXO1-3A, or NGFR negative control challenged with Nalm6 leukemia cells at a 1:4 effector:target ratio on days 14, 17, 20, and 24 of culture. IFNγ secretion after the fourth tumor challenge was measured in two donors after 24 hours of CAR T cell-tumor coculture ( Fig.19A ). The data show that IFNγ secretion was better in cells engineered to overexpress FOXO1-WT compared to NGFR negative control or cells overexpressing FOXO1-3A. Error bars show standard deviation of 3 independent wells. Fig.19B Figure 2 is a graph of the number of CD8+CAR T cells after repeated tumor challenge. In both donors, CD8+ cells overexpressing FOXO1-WT expanded the most in response to serial tumor challenge. Cells were counted 3 days after tumor stimulation. Fig.19C Shown is LEF1 expression in CAR T cells measured by intracellular flow cytometry seven days after the fourth tumor stimulation (n=2 independent donors). Cells expressing FOXO1-WT had the most LEF1 expression, which correlates with a memory-like phenotype. Fig.19D CD62L expression in CAR T cells measured by surface flow cytometry seven days after the fourth tumor stimulation is shown (n=2 independent donors). Cells expressing FOXO1-WT had the most CD62L expression, which correlates with a memory-like phenotype. Fig.19A The statistical data were determined by two-tailed, unpaired student T test (***: p < 0.0005, **: p < 0.005).
[0041] Fig. 20A and 20B Shown is the metabolism of CD19.28ζCAR T cells overexpressing FOXO1-WT, FOXO1-3A, or NGFR negative control analyzed via Seahorse metabolic flux assay. Fig. 20A is a graph of oxygen consumption rate (OCR) of CAR T cells over time. FOXO1-WT overexpressing cells have the highest metabolic activity. Error bars show the standard deviation of OCR measurements from at least 9 independent wells, n=1 donor. Fig. 20B It is through Fig. 20AFigure 2. Spare respiratory capacity (SRC) of CAR T cells calculated by subtracting the OCR at time points (t) 7, 8, and 9 from time points 1, 2, and 3 in Figure 2. FOXO1-WT overexpressing CAR T cells had the greatest spare respiratory capacity, indicating significantly healthier and more robust mitochondria. Column height represents the mean of the three SRC time point comparisons; error bars show the standard deviation of the SRC measurements for the three time point comparisons (t7-t1, t8-t2, t9-t3; OCR for each time point was determined by averaging the OCR values of 9 independent wells at that time point, as shown in Figure 2. Fig. 20A shown). Fig. 20B The statistical data in the Figures were determined by two-tailed, unpaired Student's T-test (****: p<0.00005).
[0042] Fig.21 Figure 2 is an additional graph showing tumor control and survival in mice treated with FOXO1-WT and FOXO1-3A CAR-T cells compared to mice treated with untransduced (blank control), NGFR, and T cells. Fig. 12A As shown. Nalm6 cells (1e6) were transplanted into NSG mice and a subtherapeutic dose of 0.2e6 CD19.28z+ / NGFR+ T cells were infused 7 days after transplantation. The data showed enhanced tumor control and survival in mice treated with FOXO1-WT compared to mice treated with untransduced (blank control), NGFR or FOXO1-3A cells. There were 5 mice in each group. Two mice in the FOXO1-WT group were euthanized prematurely due to complications unrelated to tumor progression. Statistics were determined using the log-rank Mantel-Cox test. DETAILED DESCRIPTION
[0043] Herein, the expression and function of the master transcription factor FOXO1, wild type (FOXO1-WT) or nuclear restricted mutant FOXO1 (FOXO1-AAA) are used to enhance CAR-T cell therapy. The ectopic expression of FOXO1 in human CAR-T cells confers a more memory-like phenotype in vitro (based on cell surface markers), and enhances tumor killing in CAR-T cells targeting CD19 or Her2. These effects are independent of the co-stimulatory domains used in CAR (e.g., CD28 relative to 4-1BB). In addition, using an in vitro T cell exhaustion model, in which in the absence of antigen (HA-28z), high-affinity GD2 targeting CAR spontaneously aggregates and signals, the ectopic expression of FOXO1 eliminates exhaustion and leads to lower expression of inhibitory receptors, more memory-like surface phenotypes, and enhanced function of tumor response.
[0044] Constitutive expression of FOXO1-WT in CAR-T cells resulted in enhanced tumor control in vivo using the following CAR-T / xenograft models: HA-28z versus GD2-expressing Nalm6 leukemia (liquid tumor); CD19-BBz versus Nalm6 leukemia (liquid tumor); and Her2-BBz versus 143B osteosarcoma (solid tumor)
[0045] The section headings used in this section and the overall disclosure herein are for organizational purposes only and are not intended to be limiting.
[0046] 1. Definition
[0047] As used herein, the terms "comprise(s)", "include(s)", "having", "has", "can", "contain(s)" and variations thereof are intended to represent open transitional phrases, terms or words that do not exclude the possibility of additional acts or structures. As used herein, including a sequence or a SEQ ID NO generally means that at least one copy of the sequence is present in the peptide or polynucleotide. However, two or more copies are also contemplated. Unless the context clearly indicates otherwise, the singular forms "a", "and", and "the" include plural references. The present disclosure also contemplates other embodiments that "comprise", "consist of", and "consist of" the embodiments or elements provided herein, whether or not explicitly set forth.
[0048] For the recitation of numerical ranges herein, each intermediate value with the same degree of precision is expressly contemplated. For example, for the range of 6-9, in addition to 6 and 9, the values 7 and 8 are also contemplated, and for the range 6.0-7.0, the values 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 and 7.0 are expressly contemplated.
[0049] Unless otherwise defined herein, scientific and technical terms used in conjunction with the present disclosure shall have the meanings commonly understood by those of ordinary skill in the art. The meaning and scope of the terms shall be clear; however, if there is any potential ambiguity, the definitions provided herein shall take precedence over any dictionary or external definitions. In addition, unless the context requires otherwise, singular terms shall include the plural and plural terms shall include the singular.
[0050] As used herein, "nucleic acid" or "nucleic acid sequence" refers to a polymer or oligomer of pyrimidine and / or purine bases, preferably cytosine, thymine and uracil, and adenine and guanine, respectively (see Albert L. Lehninger, Principles of Biochemistry, at 793-800 (Worth Pub. 1982)). The present technology contemplates any deoxyribonucleotide, ribonucleotide or peptide nucleic acid component and any chemical variant thereof, such as methylated, hydroxymethylated or glycosylated forms of these bases, etc. The composition of the polymer or oligomer can be heterogeneous or homogeneous, and can be isolated from naturally occurring sources or can be artificially or synthetically produced. In addition, the nucleic acid can be DNA or RNA, or a mixture thereof, and can exist permanently or temporarily in single-stranded or double-stranded form, including homoduplexes, heteroduplexes and hybrid states. In some embodiments, the nucleic acid or nucleic acid sequence includes other types of nucleic acid structures such as, for example, DNA / RNA helices, peptide nucleic acids (PNAs), morpholino nucleic acids (see, for example, Braasch and Corey, Biochemistry, 41(14):4503-4510 (2002)) and U.S. Pat. No. 5,034,506), locked nucleic acids (LNAs; see Wahlestedt et al., Proc. Natl. Acad. Sci. USA, 97:5633-5638 (2000)), cyclohexenyl nucleic acids (see Wang, J. Am. Chem. Soc., 122:8595-8602 (2000)) and / or ribozymes. The term "nucleic acid" or "nucleic acid sequence" may also encompass chains comprising non-natural nucleotides, modified nucleotides and / or non-nucleotide building blocks that may exhibit the same functions as natural nucleotides (e.g., "nucleotide analogs"); in addition, as used herein, the term "nucleic acid sequence" refers to oligonucleotides, nucleotides or polynucleotides, and fragments or portions thereof, as well as DNA or RNA of genomic or synthetic origin, which may be single-stranded or double-stranded, and represent sense or antisense strands. The terms "nucleic acid," "polynucleotide," "nucleotide sequence," and "oligonucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, deoxyribonucleotides or ribonucleotides, or analogs thereof.
[0051] As used herein, the term "percent sequence identity" refers to the percentage of nucleotides or nucleotide analogs in a nucleic acid sequence or amino acids in an amino acid sequence that are identical to the corresponding nucleotides or amino acids in a reference sequence, after aligning the two sequences and introducing gaps (if necessary) to achieve the maximum percent identity. Many mathematical algorithms are known for obtaining optimal alignments and calculating the identity between two or more sequences, and these algorithms are incorporated into many available software programs. Examples of such programs include CLUSTAL-W, T-Coffee, and ALIGN (for nucleic acid and amino acid sequence alignments), BLAST programs (e.g., BLAST 2.1, BL2SEQ, and higher versions thereof), and FASTA programs (e.g., FASTA3x, FAS TM and SSEARCH) (for sequence alignment and sequence similarity searches). Sequence alignment algorithms are also disclosed in, for example, Altschul et al., J. Molecular Biol., 215(3):403-410 (1990), Beigert et al., Proc. Natl. Acad. Sci. USA, 106(10):3770-3775 (2009), Durbin et al., eds., Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids, Cambridge University Press, Cambridge, UK (2009), Soding, Bioinformatics, 21(7):951-960 (2005), Altschul et al., Nucleic Acids Res., 25(17):3389-3402 (1997) and Gusfield, Algorithms on Strings, Trees and Sequences, Cambridge University Press, Cambridge UK (1997)).
[0052] As used herein, the terms "providing", "administering", "introducing" are used interchangeably herein and refer to placing the composition of the present disclosure in a subject by a method or route that results in at least partial localization of the composition to a desired site. The composition can be administered by any appropriate route that results in delivery to a desired location in a subject.
[0053] A "subject" or "patient" can be human or non-human, and can include, for example, animal strains or species used as "model systems" for research purposes, such as the mouse model described herein. Likewise, patients can include adults or adolescents (e.g., children). In addition, a patient can mean any living organism, preferably a mammal (e.g., human and non-human), that can benefit from the administration of the compositions contemplated herein. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates, such as chimpanzees and other apes and monkey species; farm animals, such as cattle, horses, sheep, goats, pigs; livestock, such as rabbits, dogs and cats; experimental animals, including rodents, such as rats, mice and guinea pigs, etc. Examples of non-mammals include, but are not limited to, birds, fish, etc. In one embodiment, the mammal is a human.
[0054] As used herein, "treat," "treating," and the like means slowing, stopping, or reversing the progression of a disease or disorder when a compound or composition described herein is provided to an appropriate control subject. The term also means reversing the progression of such a disease or disorder to the extent that symptoms are eliminated or greatly alleviated. Thus, "treating" means administering or administering a composition described herein to a subject, wherein the subject suffers from a disease or symptom of a disease, wherein the purpose is to cure, heal, alleviate, relieve, alter, remedy, improve, ameliorate, or affect the disease or symptom of a disease.
[0055] A "vector" or "expression vector" is a replicon, such as a plasmid, phage, virus or cosmid, into which another DNA segment, such as an "insert segment", can be attached or integrated to allow replication of the attached segment in the cell.
[0056] 2. Composition
[0057] Provided herein are compositions comprising isolated T cells comprising an exogenous nucleic acid encoding forkhead box protein O1 (FOXO1).
[0058] In some embodiments, FOXO1 is wild-type FOXO1. In some embodiments, FOXO1 comprises an amino acid sequence having at least about 70% (about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, about 98%, about 99%, or 100%) similarity to SEQ ID NO:1. In some embodiments, FOXO1 comprises an amino acid sequence of SEQ ID NO:1.
[0059] In some embodiments, FOXO1 is a fully or partially nuclear restricted FOXO1 (e.g., FOXO1-AAA or FOXO1-3A as disclosed herein). In some embodiments, FOXO1 comprises an amino acid sequence having at least about 70% (about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, about 98%, about 99%, or 100%) similarity to SEQ ID NO:2. In some embodiments, FOXO1 comprises the amino acid sequence of SEQ ID NO:2. In some embodiments, FOXO1 is not a nuclear restricted FOXO1. In some embodiments, FOXO1 is a partially nuclear restricted FOXO1, e.g., a variant of FOXO1 that has an increased likelihood of residing in the nucleus of a cell compared to the wild type, but is not fully nuclear restricted. In some embodiments, FOXO1 is not a partially nuclear restricted FOXO1.
[0060] SEQ ID NO:1
[0061] MAEAPQVVEIDPDFEPLPRPRSCTWPLPRPEFSQSNSATSSPAPSGSAAANPDAAAGLPSASAAAVSADFMSNLSLLEESEDFPQAPGSVAAAVAAAAAAAATGGLCGDFQGPEAGCLHPAPPQPPPPGPLSQHPPVPPAAAGPLAGQPRKSSSSRRNAWGNLSYADLITKAIESSAEKRLTLSQIYEWMVKSVPYFKDKGDSNSSAGWKNSIRHNLSLHSKFIRVQNEGTGKSSWWMLNPEGGKSGKSPRRRAASMDNNSKFAKSRSRAAKKKASLQSGQEGAGDSPGSQFSKWPASPGSHSNDDFDNWSTFRPRTSSNASTISGRLSPIMTEQDDLGEGDVHSMVYPPSAAKMASTLPSLSEISNPENMENLLDNLNLLSSPTSLTVSTQSSPGTMMQQTPCYSFAPPNTSLNSPSPNYQKYTYGQSSMSPLPQMPIQTLQDNKSSYGGMSQYNCAPGLLKELLTSDSPPHNDIMTPVDPGVAQPNSRVLGQNVMMGPNSVMSTYGSQASHNKMMNPSSHTHPGHAQQTSAVNGRPLPHTVSTMPHTSGMNRLTQVKTPVQVPLPHPMQMSALGGYSSVSSCNGYGRMGLLHQEKLPSDLDGMFIERLDCDMESIIRNDLMDGDTLDFNFDNVLPNQSFPHSVKTTTHSWVSG
[0062] SEQ ID NO:2
[0063] MAEAPQVVEIDPDFEPLPRPRSCAWPLPRPEFSQSNSATSSPAPSGSAAANPDAAAGLPSASAAAVSADFMSNLSLLEESEDFPQAPGSVAAAVAAAAAAAATGGLCGDFQGPEAGCLHPAPPQPPPPGPLSQHPPVPPAAAGPLAGQPRKSSSSRRNAWGNL SYADLITKAIESSAEKRLTLSQIYEWMVKSVPYFKDKGDSNSSAGWKNSIRHNLSLHSKFIRVQNEGTGKSSWWMLNPEGGKSGKSPRRRAAAMDNNSKFAKSRSRAAKKKASLQSGQEGAGDSPGSQFSKWPASPGSHSNDDFDNWSTFRPRTSANASTISGR LSPIMTEQDDLGEGDVHSMVYPPSAAKMASTLPSLSEISNPENMENLLDNLNLLSSPTSLTVSTQSSPGTMMQQTPCYSFAPPNTSLNSPSPNYQKYTYGQSSMSPLPQMPIQTLQDNKSSYGGMSQYNCAPGLLKELLTSDSPPHNDIMTPVDPGVAQPNSRV LGQNVMMGPNSVMSTYGSQASHNKMMNPSSHTHPGHAQQTSAVNGRPLPHTVSTMPHTSGMNRLTQVKTPVQVPLPHPMQMSALGGYSSVSSCNGYGRMGLLHQEKLPSDLDGMFIERLDCDMESIIRNDLMDGDTLDFNFDNVLPNQSFPHSVKTTTHSWVSG
[0064] FOXO1 suitable for use in the disclosed compositions and methods may include one or more amino acid substitutions or truncations compared to the corresponding wild-type protein or SEQ ID NO: 1. In some embodiments, FOXO1 is a functional fragment of wild-type FOXO1 or SEQ ID NO: 1. In some embodiments, FOXO1 is a functional variant of wild-type FOXO1 or SEQ ID NO: 1, such that the primary amino acid sequence may contain one or more substitutions, while the resulting polypeptide retains its expression level, cellular localization and / or activity (e.g., promoting and maintaining a CAR-T cell memory phenotype and / or upregulating known transcription factors that drive stemness and effector transcriptional programs). The functional variant preferably retains greater than 50% of the activity of the original polypeptide (e.g., preventing T cell exhaustion).
[0065] Amino acid "substitution" or "replacement" refers to the replacement of an amino acid at a given position or residue with another amino acid at the same position or residue within a polypeptide sequence. Amino acids are broadly classified as "aromatic" or "aliphatic". Aromatic amino acids include aromatic rings. Examples of "aromatic" amino acids include histidine (H or His), phenylalanine (F or Phe), tyrosine (Y or Tyr), and tryptophan (W or Trp). Non-aromatic amino acids are broadly classified as "aliphatic". Examples of "aliphatic" amino acids include glycine (G or Gly), alanine (A or Ala), valine (V or Val), leucine (L or Leu), isoleucine (I or He), methionine (M or Met), serine (S or Ser), threonine (T or Thr), cysteine (C or Cys), proline (P or Pro), glutamate (E or Glu), aspartic acid (A or Asp), asparagine (N or Asn), glutamine (Q or Gin), lysine (K or Lys), and arginine (R or Arg).
[0066] Amino acid replacements or substitutions can be conservative, semi-conservative or non-conservative. The phrase "conservative amino acid replacement" or "conservative mutation" refers to the replacement of one amino acid with another amino acid having a common property. A practical method for defining common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz and Schirmer, Principles of Protein Structure, Springer-Verlag, New York (1979)). Based on such analysis, amino acid groups can be defined in which the amino acids within the group are preferentially interchanged with each other and are therefore most similar to each other in terms of the impact on the overall protein structure (Schulz and Schirmer, above).
[0067] Examples of conservative amino acid substitutions include amino acid substitutions within the above subgroups, e.g., lysine replaces arginine, and vice versa, so that a positive charge can be maintained, glutamic acid replaces aspartic acid and, vice versa, so that a negative charge can be maintained, serine replaces threonine, so that free-OH can be maintained, and glutamine replaces asparagine, so that free-NH2 can be maintained. "Semi-conservative mutations" include amino acid substitutions within the same group but not within the same subgroup as described above. For example, aspartic acid replaces asparagine, or asparagine replaces lysine, involving amino acids within the same group but in different subgroups. "Non-conservative mutations" involve amino acid substitutions between different groups, e.g., lysine replaces tryptophan, or phenylalanine replaces serine, etc.
[0068] The exogenous nucleic acid promotes overexpression of FOXO1 in T cells. The expression of FOXO1 can be constitutive, regulatable or inducible, cell type specific, tissue specific or species specific. In selected embodiments, the isolated T cells constitutively express FOXO1 by the exogenous nucleic acid.
[0069] In some embodiments, under conditions where unmodified T cells (T cells that do not express FOXO1 from exogenous nucleic acids) exhibit exhaustion, the T cells remain functional (e.g., maintain the functionality of T cells exposed to excess antigen). "T cell exhaustion" refers to a loss of T cell function that may occur due to infection (e.g., chronic infection) or disease. T cell exhaustion is associated with increased expression of exhaustion markers and inhibitory receptors (e.g., PD-1, TIM-3, and LAG-3), decreased apoptosis, and cytokine secretion.
[0070] In some embodiments, FOXO1 is fused to a motif that regulates expression levels or enhances intracellular degradation (e.g., a degron, an instability domain, etc.). The motif can be fused to the N-terminus or C-terminus of FOXO1. The motif can be attached to FOXO1 via a linker.
[0071] In some embodiments, FOXO1 is fused to a destabilization domain (DD). A destabilization domain is a protein domain that modulates the stability of a payload (e.g., a target protein (e.g., FOXO1)) fused to the DD due to the presence or absence of a binding ligand (e.g., a small molecule or drug). For example, in the absence of a binding ligand, some destabilization domains cause the ubiquitin-proteasome system to recognize and degrade the payload fused to the DD. In the presence of its binding ligand, the fused DD and payload are stable. In some cases, stability is dose-dependent. Therefore, the presence, absence, or amount of a small molecule ligand that binds or interacts with a DD can modulate the stability of FOXO1 following such binding or interaction, thereby modulating the function of FOXO1. Thus, the presence of an adjustable destabilization domain allows the concentration of FOXO1 to be modulated over time with a cognate binding ligand.
[0072] In some embodiments, FOXO1 is fused to a degradation determinant or one or more degradation determinants. As used herein, a "degradation determinant" is a single amino acid or peptide that can target FOXO1 for degradation. Any suitable degradation determinant can be used as long as it is considered suitable for the intended use based on the disclosure herein. Degradation determinants include portions of proteins that signal and / or target degradation (or otherwise increase the rate of degradation) to the protein to which the degradation determinant is attached or otherwise associated (e.g., grafted thereon). Non-limiting examples of degradation determinants include short amino acid sequences, structural motifs, exposed amino acids, etc. Degradation determinants can be of prokaryotic or eukaryotic origin and can be used in naturally occurring or non-naturally occurring (i.e., recombinant) form. Degraders can be post-translationally modified to target proteins for degradation, wherein such post-translational modifications include, but are not limited to, for example, ubiquitination, proteolytic cleavage, phosphorylation, methylation, ADP-ribosylation, AMPylation, lipidation, alkylation, nitrosylation, succinylation, SUMOylation, neddylation, ISGylation, etc. Useful degraders include ubiquitin-dependent degraders and ubiquitin-independent degraders. For example, in some cases, ubiquitin-independent proteasome degradation targeting proteins can be achieved by attaching ornithine decarboxylase (ODC) degraders (including, but not limited to, for example, mammalian ODC, such as, for example, rodent ODC, including, but not limited to, for example, c-terminal mouse ODC (cODC)). In some cases, useful degrons include degrons described in Takeuchi et al., Biochem. J (2008) 410: 401-407 and / or Matsuzawa et al., PNAS (2005) 102 (42): 14982-7; the disclosures of which are incorporated herein by reference in their entirety. In some cases, a protein can be targeted for ubiquitin-independent proteasomal degradation by post-translational modification of the degron (including, but not limited to, for example, proteolytic cleavage, phosphorylation, methylation, ADP-ribosylation, AMPylation, lipidation, alkylation, nitrosylation, succinylation, SUMOylation, pseudo-synthesis, ISGylation), wherein such modification directly or indirectly results in partial or complete unfolding of the protein or other mechanisms leading to protein degradation.
[0073] The present invention is not limited by the type of T cells modified to overexpress and / or include an exogenous nucleic acid molecule encoding FOXO1. The T cells can be selected from CD3+T cells, CD8+T cells, CD4+T cells, natural killer (NK) T cells, αβT cells, γδT cells, or any combination thereof (e.g., a combination of CD4+ and CD8+T cells). In some embodiments, the T cells are memory T cells (e.g., central memory T cells or effector memory T cells). In some embodiments, the T cells are tumor infiltrating lymphocytes. In some embodiments, the T cells are cytokine-induced killer cells.
[0074] In some embodiments, T cells are naturally occurring T cells. For example, T cells can be separated from subject samples. In some embodiments, T cells are anti-tumor T cells (e.g., T cells with activity against tumors (e.g., autologous tumors), which become activated and amplified in response to antigens). Anti-tumor T cells include but are not limited to T cells (e.g., tumor infiltrating lymphocytes (TILs)) obtained from resected tumors or tumor biopsies and polyclonal or monoclonal tumor reactive T cells (e.g., obtained by plasmapheresis, for tumor antigens presented by autologous or artificial antigen presenting cells, ex vivo amplification). In some embodiments, T cells are ex vivo amplified.
[0075] In some embodiments, the isolated T cell further includes a nucleic acid encoding a recombinant receptor. In some embodiments, the recombinant receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR).
[0076] In certain embodiments, T cells are genetically modified with recombinant receptors that recognize and respond to tumor antigens. Such receptors are typically composed of an extracellular domain comprising a single-chain antibody (scFv) specific for a tumor antigen, linked to an intracellular T cell signaling motif (see, e.g., Westwood, JA et al, 2005, Proc. Natl. Acad. Sci., USA, 102(52): 19051-19056).
[0077] The present invention is not limited by the type of tumor antigen identified. As used herein, the term "tumor antigen" refers to any molecule (e.g., protein, peptide, lipid, carbohydrate, etc.) expressed or overexpressed by tumor cells or cancer cells alone or mainly, so that the antigen is related to a tumor or cancer. Cancer antigens can also be expressed by normal, non-tumor or non-cancer cells. However, in this case, the expression of cancer antigens by normal, non-tumor or non-cancer cells is not as strong as the expression by tumor or cancer cells. In this regard, compared with the expression of antigens by normal, non-tumor or non-cancer cells, tumors or cancer cells can overexpress antigens or express antigens at significantly higher levels. In addition, cancer antigens can be additionally expressed by cells of different developmental or mature states. For example, cancer antigens can be additionally expressed by cells in embryonic or fetal stages, which are generally not present in adults. Alternatively, cancer antigens can be additionally expressed by stem cells or precursor cells, which are generally not present in adults.
[0078] A cancer antigen can be an antigen expressed by any cell of any cancer or tumor. A cancer antigen can be a cancer antigen of only one type of cancer or tumor, such that the cancer antigen is associated with or has the characteristics of only one type of cancer or tumor. Alternatively, a cancer antigen can be a cancer antigen of more than one type of cancer or tumor (e.g., can be characteristic). For example, a cancer antigen can be expressed by breast cancer and prostate cancer cells, while normal, non-tumor or non-cancer cells do not express it at all. Exemplary cancer antigens include, but are not limited to, glycoprotein 100 (gp100), melanoma antigen 1 recognized by T cells (MART-1), melanoma antigen gene (MAGE) family members (e.g., MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-A12), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), intravascular VEGFR-2, glioma-associated antigen, carcinoembryonic antigen (CEA), beta-human chorionic gonadotropin, alpha-fetoprotein (AFP), lectin-reactive AFP, thyroglobulin, human telomerase reverse transcriptase, prostate-specific antigen (PSA), prostate cancer tumor antigen-1 (PCTA-1), insulin growth factor (IGF)-I, IGF-II, IGF-I receptor, intestinal carboxylesterase, human epidermal growth factor receptor 2 (HER-2), mesothelin, and epidermal growth factor receptor variant III (EGFR III).
[0079] Any T cell comprising a receptor that recognizes a tumor antigen can be used in the compositions and methods of the invention. Examples include, but are not limited to, T cells expressing a receptor (e.g., a native or naturally occurring receptor, or a receptor engineered to express a synthetic receptor such as an engineered TCR or CAR) that recognizes an antigen selected from: CD19, CD20, CD22, receptor tyrosine kinase-like orphan receptor 1 (ROR1), disialoganglioside 2 (GD2), Epstein-Barr virus (EBV) protein or antigen, folate receptor, mesothelin, human carcinoembryonic antigen (CEA), prostatic acid phosphatase (PAP), CD33 / IL3R, tyrosine protein kinase Met (c-Met) or hepatocyte growth factor receptor (HGFR), prostate-specific membrane antigen (PSMA), glycolipid F77, epidermal growth factor receptor variant III (EGFRvIII), NY-ESO-1, melanoma antigen gene (MAGE) family member A3 (MAGE-A3), melanoma antigen recognized by T cells 1 (MART-1), GP1000, p53, or other tumor antigens described herein.
[0080] In some embodiments, T cells are engineered to express chimeric antigen receptors (CAR). The present invention can use any CAR that specifically binds to a desired antigen (e.g., a tumor antigen). In some embodiments, CAR includes an antigen binding domain. In some embodiments, the antigen binding domain is a single-chain variable fragment (scFv) comprising a heavy chain and a light chain variable region that specifically binds to a desired antigen. In some embodiments, CAR further includes a transmembrane domain (e.g., a T cell transmembrane domain (e.g., a CD28 transmembrane domain)) and a signaling domain including one or more immunoreceptor tyrosine-based activation motifs (ITAMs) (e.g., a T cell receptor signaling domain (e.g., TCR ζ chain)). In some embodiments, CAR includes one or more costimulatory domains (e.g., a domain that provides a second signal to stimulate T cell activation). The present invention is not limited by the type of costimulatory domain. In fact, any costimulatory domain known in the art can be used, including but not limited to CD28, OX40 / CD134, 4-1BB / CD137 / TNFRSF9, high affinity immunoglobulin E receptor-γ subunit, FcERIγ, ICOS / CD278, interleukin 2 subunit β (ILRβ) or CD122, cytokine receptor common subunit γ (IL-2Rγ) or CD132 and CD40. In some embodiments, the costimulatory domain is 4-1BB. In some embodiments, the costimulatory domain is CD28.
[0081] CAR can include a target-specific binding element, also referred to as an antigen binding portion. The selection of the portion depends on the type and quantity of the ligand that defines the surface of the target cell. For example, an antigen binding domain can be selected to identify a ligand that acts as a cell surface marker on a target cell associated with a specific disease state. Examples of cell surface markers that can serve as ligands for the antigen portion domains in the CAR of the present invention include those associated with viruses, bacteria and parasitic infections, autoimmune diseases, and cancer cells as described above.
[0082] Depending on the desired antigen to be targeted, CAR can be engineered to include an appropriate antigen binding portion specific for the desired antigen target. For example, if CD19 is a desired antigen to be targeted, an antibody to CD19 can be used as an antigen binding portion to be incorporated into the CAR of the present invention.
[0083] FOXO1 and the engineered receptor can be encoded by the same or different nucleic acids. In some embodiments, FOXO1 and the engineered receptor are encoded by a single nucleic acid. In some embodiments, FOXO1 and the engineered receptor are encoded by separate nucleic acids. The one or more nucleic acids may include DNA or RNA (e.g., mRNA). In some embodiments, the one or more nucleic acids include a vector.
[0084] FOXO1 and the engineered receptor can be expressed using the same, similar (e.g., both are weak or both are strong), or different promoters. For example, the promoter of FOXO1 can confer a high transcription rate (strong promoter), while the promoter of the engineered receptor can confer a low transcription rate (weak promoter), or vice versa. In some embodiments, the promoters of FOXO1 and the engineered receptor can confer a high transcription rate (strong promoter). In some embodiments, the promoters of FOXO1 and the engineered receptor can confer a low transcription rate (weak promoter). Many promoter libraries have been experimentally established, and the selection of promoters and promoter strength are well known to those skilled in the art.
[0085] In addition, nucleic acids disclosed herein may include constitutive, adjustable or inducible, cell type specific, tissue specific or species specific promoters. In addition to sequences sufficient to guide transcription, promoters may also include sequences (e.g., enhancers, Kozak sequences and introns) that participate in regulating other regulatory elements of transcription. Many promoters / regulatory sequences for driving constitutive expression are available in the art, and include but are not limited to, for example, CMV (cytomegalovirus promoter), EF1a (human elongation factor 1α promoter), SV40 (simian vacuolating virus 40 promoter), PGK (mammalian phosphoglycerate kinase promoter), Ubc (human ubiquitin C promoter), human β-actin promoter, rodent β-actin promoter, CBh (chicken β-actin promoter), CAG (comprising a hybrid promoter of CMV enhancer, chicken β-actin promoter and rabbit β-globin splicing acceptor), TRE (tetracycline response element promoter), H1 (human polymerase III RNA promoter), U6 (human U6 small nuclear promoter), etc. Additional promoters that can be used for expression include, but are not limited to, cytomegalovirus (CMV) intermediate early promoter, viral LTRs (such as Rous sarcoma virus LTR, HIV-LTR, HTLV-1 LTR, Maloney murine leukemia virus (MMLV) LTR, myeloproliferative sarcoma virus (MPSV) LTR, spleen focus forming virus (SFFV) LTR), simian virus 40 (SV40) early promoter, herpes simplex tk virus promoter, elongation factor 1-alpha (EF1-alpha) promoter with or without EF1-alpha intron. Additional promoters include any constitutively active promoter. Alternatively, any regulatable promoter can be used so that its expression can be regulated within the cell.
[0086] In addition, inducible expression can be achieved by placing the nucleic acid encoding this type of molecule under the control of an inducible promoter / regulatory sequence. Promoters well known in the art can be induced in response to inducing agents such as metals, glucocorticoids, tetracycline, hormones, etc., and are also considered for use in the present invention. Therefore, it should be understood that the present disclosure includes the use of any promoter / regulatory sequence known in the art that can drive the expression of the desired protein operably connected thereto.
[0087] The disclosure also provides vectors comprising nucleic acids and cells comprising nucleic acids or their vectors. Vectors can be used to propagate nucleic acids and / or allow expression of nucleic acids (e.g., expression vectors) in appropriate cells. Those of ordinary skill in the art will appreciate the various vectors that can be used to propagate and express nucleic acid sequences.
[0088] Expression vectors for stable or transient expression can be constructed and introduced into cells via conventional methods. For example, the nucleic acid can be cloned into a suitable expression vector, such as a plasmid or viral vector operably linked to a suitable promoter. The selection of expression vectors / plasmids / viral vectors is preferably suitable for integration and replication in eukaryotic cells.
[0089] In certain embodiments, the vectors disclosed herein can use mammalian expression vectors to drive expression of one or more sequences in mammalian cells. Examples of mammalian expression vectors include pCDM8 (Seed, Nature (1987) 329: 840, which is incorporated herein by reference) and pMT2PC (Kaufman, et al., EMBO J. (1987) 6: 187, which is incorporated herein by reference). When used in mammalian cells, the control function of the expression vector is usually provided by one or more regulatory elements. For example, commonly used promoters are derived from polyoma virus, adenovirus 2, cytomegalovirus, simian virus 40, and other promoters disclosed herein and known in the art. For other suitable expression systems for prokaryotic and eukaryotic cells, see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd eds., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, which is incorporated herein by reference.
[0090] In addition, the vector may include, for example, some or all of the following: a selectable marker gene for selecting stable or transient transfectants in a host cell; transcription termination and RNA processing signals; 5'- and 3'-untranslated regions; internal ribosome binding sites (IRESes), a multifunctional multiple cloning site; and a reporter gene for evaluating chimeric receptor expression. Suitable vectors and methods for producing vectors containing transgenes are well known and available in the art. Selectable markers include chloramphenicol resistance, tetracycline resistance, spectinomycin resistance, neomycin, streptomycin resistance, erythromycin resistance, rifampicin resistance, bleomycin resistance, heat-adapted kanamycin resistance, gentamycin resistance, hygromycin resistance, trimethoprim resistance, dihydrofolate reductase (DHFR), GPT; URA3, HIS4, LEU2 and TRP1 genes of S. cerevisiae.
[0091] When introduced into a cell, the vector may be maintained as an autonomously replicating sequence or extrachromosomal element, or may be integrated into the host DNA.The nucleic acid may be delivered to the cell by any suitable means.
[0092] Conventional viral and non-viral gene transfer methods can be used to introduce nucleic acids into cells. Such methods can be used to administer nucleic acids to cells in culture or host organisms. Non-viral vector delivery systems include DNA plasmids, cosmids, RNA (e.g., transcripts of vectors described herein), nucleic acids, and nucleic acids complexed with delivery vehicles.
[0093] Viral vector delivery systems include DNA and RNA viruses, which have free genomes or integrated genomes after delivery to cells. Various viral constructs can be used to deliver the present nucleic acid to cells. Viral vectors include, for example, retroviruses, slow viruses, adenoviruses, adeno-associated and herpes simplex virus vectors. Non-limiting examples of such recombinant viruses include recombinant adeno-associated viruses (AAV), recombinant adenoviruses, recombinant slow viruses, recombinant retroviruses, recombinant herpes simplex viruses, recombinant poxviruses, bacteriophages, etc. The present disclosure provides vectors that can be integrated into the host genome, such as retroviruses or slow viruses. See, for example, Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989; Kay, MA, et al., 2001 Nat. Medic. 7 (1): 33-40; and Walther W. and Stein U., 2000 Drugs, 60 (2): 249-71, which are incorporated herein by reference.
[0094] Vectors according to the present disclosure can be transformed, transfected or otherwise introduced into cells. Transfection refers to the uptake of vectors by cells, whether or not any coding sequence is actually expressed. Many transfection methods are known to those of ordinary skill, for example, lipofectamine, calcium phosphate coprecipitation, electroporation, DEAE-dextran treatment, microinjection, viral infection and other methods known in the art. Transduction refers to the entry of viruses into cells and the expression (e.g., transcription and / or translation) of sequences delivered by viral vector genomes. In the case of recombinant vectors, "transduction" generally refers to the entry of recombinant viral vectors into cells and the expression of the target nucleic acid delivered by the vector genome.
[0095] Methods for delivering vectors to cells are well known in the art and may include DNA or RNA electroporation, transfection agents (such as liposomes or nanoparticles) to deliver DNA or RNA; delivery of DNA, RNA or protein by mechanical deformation (see, e.g., Sharei et al. Proc. Natl. Acad. Sci. USA (2013) 110(6): 2082-2087, which is incorporated herein by reference); or viral transduction. In some embodiments, the vector is delivered to the cell by viral transduction. Nucleic acids can be delivered as part of a larger construct (such as a plasmid or viral vector), or delivered directly, e.g., by electroporation, lipid vesicles, viral transporters, microinjection, and gene gun (high-speed particle bombardment).
[0096] In addition, delivery vehicles such as nanoparticle-based and lipid-based delivery systems can be used. Other examples of delivery vehicles include lentiviral vectors, ribonucleoprotein (RNP) complexes, lipid-based delivery systems, gene guns, hydrodynamics, electroporation or nuclear transfection microinjection and gene guns. Nayerossadat et al. (Adv Biomed Res. 2012; 1: 27) and Ibraheem et al. (Int J Pharm. 2014 Jan 1; 459 (1-2): 70-83 discuss various gene delivery methods in detail, which are incorporated herein by reference.
[0097] The composition can optionally include at least one additional therapeutic agent, such as other drugs for treating T cell exhaustion (e.g., anti-PD-1 checkpoint inhibitors such as nivolumab), or other drugs for treating an infection or disease associated with T cell exhaustion in a subject (e.g., an antiviral drug, an antibiotic, an antimicrobial drug, or an anticancer drug).
[0098] In some embodiments, the at least one additional therapeutic agent comprises at least one chemotherapeutic agent.As used herein, the term "chemotherapeutic agent" or "anti-cancer drug" includes any small molecule or other drug used for cancer treatment or prevention. Chemotherapeutic agents include, but are not limited to, cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, docetaxel, daunorubicin, bleomycin, vinblastine, dacarbazine, cisplatin, paclitaxel, raloxifene hydrochloride, tamoxifen citrate, abemacicilib, afinitor (Everolimus), alpelisib, anastrozole, pamidronate, anastrozole, exemestane, capecitabine, epirubicin hydrochloride, eribulin mesylate, In some embodiments, the chemotherapeutic agent comprises paclitaxel.
[0099] Compositions can include, for example, cytokines, chemokines and other biological signaling molecules, tumor-specific vaccines, cellular cancer vaccines (e.g., GM-CSF-transduced cancer cells), tumor-specific monoclonal antibodies, autologous and allogeneic stem cell rescue (e.g., enhancing graft-versus-tumor effect), other therapeutic antibodies, molecular targeted therapies, anti-angiogenic therapies, infectious agents with therapeutic intent (such as tumor-localized bacteria), and gene therapies.
[0100] The composition may include a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" means a non-toxic, inert solid, semisolid or liquid filler, diluent, encapsulating material, surfactant, cyclodextrin or any type of formulation aid. The carrier may include a single component or a combination of two or more components. Some examples of materials that can be used as pharmaceutically acceptable carriers are sugars, such as but not limited to lactose, glucose and sucrose; starches, such as but not limited to corn starch and potato starch; cellulose and its derivatives, such as but not limited to sodium carboxymethylcellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as but not limited to cocoa butter and suppository waxes; oils, such as but not limited to peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; surfactants, such as but not limited to cremophor EL, cremophor RH 60, Solutol HS15 and polysorbate 80; cyclodextrins, such as but not limited to α-CD, β-CD, γ-CD, HP-β-CD, SBE-β-CD; ethylene glycol; such as propylene glycol; esters, such as but not limited to ethyl oleate and ethyl laurate; agar; buffers, such as but not limited to magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol and phosphate buffer solution, and according to the judgment of the formulator, other non-toxic compatible lubricants (such as but not limited to sodium lauryl sulfate and magnesium stearate), preservatives and antioxidants may also be present in the composition.
[0101] The route of administration and the form of the composition will determine the type of carrier used. The composition can be in a variety of forms, for example, suitable for systemic administration (e.g., oral, rectal, nasal, sublingual, buccal, implant or parenteral injection) or topical administration (e.g., dermal, pulmonary, nasal, otic, ocular, liposome delivery system or iontophoresis).
[0102] 3. Methods
[0103] The present disclosure also provides methods for treating diseases or disorders. In some embodiments, the method comprises administering to a subject an effective amount of T cells modified to express and / or contain elevated levels of FOXO1. In some embodiments, the method comprises administering to a subject an effective amount of a composition as described herein. The present invention is not limited by the type of disease or disorder treated. Any disease or disorder that can be treated via administration of T cells can be treated in an improved and more effective manner using the compositions and methods of the present invention (e.g., containing and / or using T cells modified to express and / or contain elevated levels of FOXO1).
[0104] In some embodiments, administration inhibits or reduces T cell exhaustion (e.g., compared to a subject receiving the same amount of engineered T cells (e.g., CAR T cells or T cells comprising a recombinant TCR) that are not modified to express and / or contain elevated levels of FOXO1). In some embodiments, administration results in lower expression of inhibitory receptors (e.g., programmed cell death 1 (PDCD1, also known as PD1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)) compared to administration of unmodified T cells.
[0105] In some embodiments, exogenous FOXO1 is expressed in T cells prior to the introduction of the recombinant receptor into the T cells. In some embodiments, exogenous FOXO1 and the recombinant receptor are introduced into the T cells simultaneously, and the expression is simultaneous or substantially simultaneous. In some embodiments, the recombinant receptor is expressed in T cells prior to the introduction of exogenous FOXO1 into the T cells.
[0106] In some embodiments, FOXO1 is overexpressed in T cells prior to exposure to an antigen.
[0107] T cells can be isolated from a subject. In some embodiments, the T cells are allogeneic to the subject. In some embodiments, the T cells are autologous to the subject. Therefore, T cells can be isolated from a sample of a subject, modified and amplified ex vivo, and returned to the subject.
[0108] In some embodiments, the disease or condition is cancer. In some embodiments, the disease or condition is an infectious disease. The present invention is not limited by the type of cancer or infectious disease. In fact, any cancer known in the art to be treated with T cell therapy can be treated with the compositions and methods of the present invention. Similarly, any infectious disease known in the art to be treated with T cell therapy can be treated with the compositions and methods of the present invention.
[0109] In certain embodiments, the present invention provides a method for treating or delaying the progression of cancer in an individual, or for treating or delaying the progression of an infectious disease in an individual, comprising administering to the individual an effective amount of a modified T cell or a composition thereof, as described herein. In some embodiments, the treatment results in a sustained response in the individual after cessation of treatment.
[0110] The method can be used for any cancer cell or subject with any type of cancer, such as those described by the National Cancer Institute. In some embodiments, the cancer can be a carcinoma, sarcoma, lymphoma, leukemia, melanoma, mesothelioma, multiple myeloma, or seminoma. In some embodiments, the cancer comprises a solid tumor. In some embodiments, the cancer is a metastatic cancer.
[0111] The cancer can be bladder cancer, blood cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colon cancer / rectum cancer, endometrial cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, muscle tissue cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, spleen cancer, stomach cancer, testicular cancer, thyroid cancer or uterine cancer.
[0112] The methods described herein can be used to treat disorders where immunogenicity enhancement is desired, such as increasing tumor immunogenicity to treat cancer. In some embodiments, recombinant receptors (e.g., CAR and / or TCR) are specific to the cancer being treated. In some embodiments, recombinant receptors (e.g., CAR and / or TCR) are universal for all cancers.
[0113] In certain embodiments, the present invention demonstrates that treating a subject with cancer with a therapeutically effective amount of a disclosed composition is superior to treating a subject with cancer with an unmodified T cell. In some embodiments, treatment with a therapeutically effective amount of a disclosed composition inhibits the development or growth of cancer cells or and / or makes cancer cells as a group more susceptible to other treatments (e.g., cell death inducing activity of cancer therapeutic drugs or radiotherapy). Therefore, the compositions and methods of the present invention can be used as a monotherapy (e.g., to kill cancer cells, and / or reduce or inhibit cancer cell growth, induce cancer cell apoptosis and / or cell cycle arrest), or when administered in combination with one or more additional agents such as other anticancer agents (e.g., cancer therapeutic drugs or radiotherapy that induce cell death or disrupt the cell cycle), so that a greater proportion of cancer cells are easy to kill, inhibit cancer cell growth, induce apoptosis and / or cell cycle arrest compared to a corresponding proportion of cells in an animal treated with only a cancer therapeutic drug or radiotherapy alone.
[0114] In some embodiments, the individual has a cancer that is resistant (e.g., has been shown to be resistant) to one or more other forms of anti-cancer treatment (e.g., chemotherapy, immunotherapy, etc.). In some embodiments, resistance includes recurrence of cancer or refractory cancer. Recurrence may refer to the reappearance of cancer at the original site or a new site after treatment. In some embodiments, resistance includes the progression of cancer during chemotherapy treatment. In some embodiments, resistance includes cancer that is unresponsive to treatment with traditional or conventional chemotherapeutic agents. Cancer can be resistant at the beginning of treatment, or can become resistant during treatment. In some embodiments, the cancer is in the early or late stages.
[0115] In some embodiments, modified T cells and compositions thereof are used to treat, ameliorate or prevent cancers characterized by resistance to one or more conventional cancer therapies (e.g., those cancer cells that are chemo-resistant, radio-resistant, hormone-resistant, etc.). In some embodiments, treatment can completely inhibit the growth of resistant cancer cells and / or render such cells as a population more sensitive to cancer therapeutic drugs or radiation therapy (e.g., to their activity in inducing cell death).
[0116] In certain embodiments, a therapeutically effective amount of a modified T cell composition reduces the number of cancer cells in such a treated patient. In certain embodiments, a therapeutically effective amount of a modified T cell composition reduces and / or eliminates the tumor burden in such a treated patient.
[0117] A variety of second therapies can be used in conjunction with the methods of the present disclosure. The second therapy can be the administration of an additional therapeutic agent or can be a second therapy that is unrelated to the administration of another agent. Such second therapies include, but are not limited to, surgery, immunotherapy, radiotherapy, or additional chemotherapeutic agents or anticancer agents.
[0118] The second therapy can be administered simultaneously with the initial therapy, or in the same composition or in a separate composition that is administered substantially simultaneously with the first composition. In some embodiments, the second therapy can be administered before or after treatment with the first therapy at a time interval ranging from hours to months.
[0119] In certain embodiments, the method further comprises administering radiation therapy to the patient. In certain embodiments, radiation therapy is administered before, simultaneously with, and / or after the patient receives a therapeutically effective amount of the modified T cell composition.
[0120] In some embodiments, the method further comprises administering one or more anticancer agents and / or one or more chemotherapeutic agents to the patient. In some embodiments, one or more anticancer agents and / or one or more chemotherapeutic agents are administered before, simultaneously and / or after the patient receives a therapeutically effective amount of the modified T cell composition. In some embodiments, compared with those patients treated with modified T cells or anticancer drugs / radiotherapy alone, a combined treatment of the patient with a therapeutically effective amount of modified T cells and an anticancer agent course produces greater tumor response and clinical benefit in such subjects. Since the dosages of all approved anticancer drugs and radiotherapy are known, the present invention contemplates various combinations of them with modified T cells.
[0121] In some embodiments, the second therapy comprises administration of an antibody. The antibody can target an antigen specifically expressed by tumor cells or an antigen shared with normal cells. In some embodiments, the antibody can target, for example, CD20, CD33, CD52, CD30, HER (also known as erbB or EGFR), VEGF, CTLA-4 (also known as CD152), epithelial cell adhesion molecule (EpCAM, also known as CD326), and PD-1 / PD-L1. Suitable antibodies include, but are not limited to, rituximab, blinatumomab, trastuzumab, gemtuzumab, alemtuzumab, ibritumomab, tositumomab, bevacizumab, cetuximab, panitumumab, ofatumumab, ipilimumab, brentuximab, pertuzumab, and the like. In some embodiments, additional therapeutic agents may include anti-PD-1 / PD-L1 antibodies, including but not limited to pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, and ipilimumab. The antibody may also be linked to a chemotherapeutic agent. Thus, in some embodiments, the antibody is an antibody-drug conjugate.
[0122] The administration of the second therapy can be administered to the subject by a variety of methods. In any use or method described herein, the administration can be by various routes known to those skilled in the art, including but not limited to oral, inhaled, intravenous, intramuscular, topical, subcutaneous, systemic and / or intraperitoneal administration to a subject in need thereof.
[0123] The present disclosure also provides a method for preventing engineered T cell exhaustion (e.g., maintaining the functionality of T cells exposed to excess antigen), comprising introducing a nucleic acid that overexpresses FOXO1 into T cells. In some embodiments, the method further comprises administering the engineered T cells to a subject in need thereof.
[0124] "Prevention of T cell exhaustion" refers to a state of functional recovery of T cells, characterized by one or more of the following: reduced expression and / or levels of one or more of PD-1, TIM-3, and LAG-3; increased memory cell formation and / or retention of memory markers (e.g., CD62L); prevention of apoptosis; increased production and / or secretion of antigen-induced cytokines (e.g., IL-2); enhanced killing ability; increased recognition of tumor targets with low surface antigens; enhanced proliferation in response to antigens; and reduced expression of inhibitory receptors (e.g., programmed cell death 1 (PDCD1, also known as PD1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)).
[0125] Thus, modified T cells can exhibit increased functionality and / or activity (e.g., increased antigen-induced cytokine production, enhanced killing ability (e.g., increased recognition of tumor targets with low surface antigens), increased memory cell formation, and / or enhanced proliferation in response to antigens) and / or reduced exhaustion characteristics (e.g., lower levels of markers or inhibitory receptors indicating exhaustion (e.g., PD-1, TIM-3, LAG-3) and / or lower levels of programmed cell death) compared to unmodified T cells. In the context of therapeutic applications, modified T cells can enhance the clinical efficacy of therapeutic agents (e.g., CAR T cells).
[0126] In some embodiments, the isolated T cell further includes a nucleic acid encoding a recombinant receptor. In some embodiments, the recombinant receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR). In some embodiments, the recombinant receptor is specific for a tumor antigen.
[0127] The description of FOXO1, recombinant receptors, nucleic acids and target antigens thereof, subjects, and diseases and disorders described above in connection with the compositions of the present invention also applies to methods of preventing exhaustion of engineered T cells.
[0128] The effective amount of the modified T cells or compositions disclosed herein can be determined based on the type of disease to be treated, the type of modified T cells, the severity and course of the disease, the individual's clinical condition, the individual's clinical history and response to treatment, and the judgment of the attending physician.
[0129] The efficacy of any method described herein (e.g., treatment of a disease or disorder) can be tested in various models known in the art (such as clinical or preclinical models). The effectiveness of treatment can refer to any one or more of the following: prolonging survival (including overall survival and progression-free survival); producing an objective response (including complete response or partial response); or improving the signs or symptoms of a disease or disorder (e.g., cancer or infectious disease).
[0130] In some embodiments, a sample is obtained prior to treatment with T cells (e.g., used alone or in combination with another therapy described herein) as a baseline for measuring the response to treatment. In some embodiments, the sample is a tissue sample (e.g., formalin-fixed and paraffin-embedded (FFPE), retained, fresh or frozen). In some embodiments, the sample is whole blood. In some embodiments, whole blood includes immune cells, circulating tumor cells, and any combination thereof.
[0131] For any exemplary cancer model, after tumors are established, mice can be placed in treatment groups that receive treatment or control treatment. Tumor size (e.g., tumor volume) is measured during the course of treatment, and overall survival is also monitored.
[0132] In some embodiments, efficacy can refer to the improvement of one or more factors according to a disclosed set of RECIST guidelines for determining the tumor state (i.e., response, stability or progression) in a cancer patient. Responsive subject can refer to the subject whose one or more cancers show improvement, for example, according to one or more factors based on RECIST standards. Unresponsive subject can refer to the subject whose one or more cancers do not show improvement, for example, according to one or more factors based on RECIST standards.
[0133] Effectiveness can also refer to an improvement in one of a plurality of immune-related response criteria (irRCs). In some embodiments, new lesions are added to the defined tumor burden and, for example, radiological progression is tracked in subsequent assessments. In some embodiments, the presence of non-target lesions is included in the assessment of complete response and is not included in the assessment of radiological progression. In some embodiments, radiological progression can be determined based solely on measurable disease and / or can be confirmed by continuous assessments >4 weeks from the date of first recording.
[0134] The present disclosure further provides kits comprising one or more reagents or other components that are useful, necessary or sufficient for practicing any of the methods described herein. For example, the kit can include FOXO1 reagents (nucleic acids, vectors, compositions, etc.), recombinant vector reagents (nucleic acids, vectors, compositions, etc.), transfection or administration reagents, negative and positive control samples (e.g., T cells or empty vector DNA), T cells, containers (e.g., microcentrifuge tubes), detection and analysis instruments, software, instructions, etc.
[0135] 4. Examples
[0136] Example 1
[0137] CAR-T cell exhaustion
[0138] CARs are synthetic proteins that most commonly combine an extracellular tumor recognition domain with an intracellular domain that synergizes the T cell receptor (TCR) machinery and enables T cells to recognize and destroy tumor cells in a major histocompatibility complex-independent manner. CAR T cells have demonstrated unprecedented response rates in hematological malignancies. However, T cell exhaustion, a process by which CD8+ T cells gradually lose effector function after chronic antigenic stimulation via TCR / CAR, has hampered their efficacy in both liquid and solid tumors. Targeted depletion via checkpoint blockade, while effective in some patients, has not reshaped the epigenetic imprint of exhaustion, converted exhausted cells into memory cells, or improved CAR T cell efficacy, emphasizing the need for alternative approaches.
[0139] A novel model was created in which T cells express a high-affinity GD2-targeting CAR (HA-28z) that signals in a tonic manner in the absence of antigen due to spontaneous CAR aggregation, thereby mimicking sustained antigen exposure. HA-28z CAR T cells rapidly acquire phenotypic, functional, transcriptional, and epigenetic features of exhaustion. To test whether transient disruption of CAR signaling functionally reactivates exhausted CAR T cells and promotes memory, the HA-28z CAR was modified with a C-terminal destabilizing domain (DD), which enables drug-dependent control of CAR protein, antitumor function, and tonic signaling ( Figure 1A-1B ). Transient downregulation of HA-28z CAR and cessation or “quiescence” of tonic CAR signaling ( Figure 1C ) reverses dysfunction, reduces inhibitory receptor expression, and promotes a memory-like phenotype. REST also induces global transcriptional and epigenetic reprogramming of exhausted CAR T cells, restoring them to a state closer to healthy, memory-like CAR T cells. Epigenetic changes include increased accessibility of binding motifs for memory-associated transcription factors (e.g., FOXO family transcription factors, TCF7) in resting cells ( Fig.17 ), thus indicating the activity of these factors in reversing or alleviating exhaustion. The reversal of quiescence-mediated dysfunction was dependent on EZH2 activity, suggesting a causal relationship between epigenetic reprogramming and enhanced CAR T cell function.
[0140] Example 2
[0141] Endogenous FOXO1 is required for CAR-T cell survival and memory formation
[0142] To explore the function of FOXO1 in human CAR-T cells, CAR-T cells were expanded in the presence of a selective FOXO1 small molecule inhibitor (FOXO1i). FOXO1i dose-dependently inhibited CAR-T cell expansion, persistence, and viability ( Figure 2AIn addition, FOXO1i significantly and dose-dependently reduced the expression of memory-related FOXO1 target genes (SEL, IL-7R, TCF7), while promoting an effector-like phenotype ( Figure 2B-2C ), indicating that endogenous FOXO1 promotes and maintains the memory phenotype in human CAR-T cells. These studies suggest that FOXO1 biology enhances the persistence and overall efficacy of engineered T cell therapies.
[0143] Example 3
[0144] Ectopic expression of TF via retroviral co-transduction
[0145] To ectopically express transcription factors (TF) in primary human T cells, a co-transduction approach was used, in which one retrovirus was used to express the CAR and a separate retrovirus was used to express a bicistronic vector with TF and a truncated nerve growth factor receptor (NGFR) ( Figure 3A ). Control CAR-T cells were co-transduced with a retrovirus expressing only NGFR. This approach enabled normalization of CAR expression between groups, maximization of TF expression, and the use of NGFR as a surrogate surface marker to identify and / or purify T cells expressing TF. Expression typically achieved was 3-5 times higher than endogenous levels ( Figure 3B ). In addition, a bicistronic vector expressing both TF and CAR under the same constitutive promoter showed similar results ( Figures 18A-18C ).
[0146] Example 4
[0147] Ectopic expression of FOXO1-WT and FOXO1-AAA does not affect CAR-T cell function during short-term activation
[0148] Single-cell phenotyping and functional assays were performed on CD19-targeted CAR-T cells with CD28 (CD19.28z) or 4-1BB (CD19.BBz) co-stimulatory domains with or without ectopic TF expression. Ectopic expression of FOXO1-WT, FOXO1-3A, and TCF1 did not significantly affect the pre-stimulation surface phenotype or the extent to which tumor-stimulated CAR-T cells upregulated activation and degranulation markers (CD69 and CD107a, respectively) (Figure 4), killed, or secreted inflammatory cytokines (Figure 5). These results suggest that ectopic FOXO1 overexpression does not improve or impede the effector function of transiently activated CAR-T cells.
[0149] Example 5
[0150] Ectopic FOXO1 upregulates endogenous LEF1 and TCF1 in resting CAR-T cells and maintains their expression during activation
[0151] Although the surface marker expression of FOXO1-overexpressing CD19 CAR-T cells was similar compared with controls at rest (Figure 4), it was speculated that FOXO1-overexpressing CAR-T cells might drive the expression of endogenous TCF1 (gene name TCF7), which is a memory- and stemness-related TF and FOXO1 target gene that is associated with the patient's response to checkpoint blockade and CAR-T cell response. In fact, intracellular flow cytometry showed that ectopic expression of FOXO1-WT and FOXO1-3A enhanced the expression of TCF1 and its related HMG-box family TF, lymphoid enhancer binding factor 1 (LEF1), in CD19 CAR-T cells at rest (Figure 6). Notably, in addition to the enhanced expression of the effector-related TFs T-box transcription factor TBX21 (Tbet) and B lymphocyte-induced maturation protein-1 (Blimp-1), the expression of these stemness-related TFs was also maintained during CAR-T cell activation (Figure 7). Together, these data suggest that FOXO1 directly and / or indirectly upregulates TFs known to drive stemness and effector transcriptional programs and confers enhanced function in the context of chronic stimulation.
[0152] Example 6
[0153] FOXO1-engineered CD19-targeted CAR-T cells exhibit enhanced functionality in a chronic antigen-mimicking model
[0154] To examine the impact of ectopic FOXO1 expression on CAR-T cell function during chronic stimulation, CD19-targeted CAR-T cells co-transduced with NGFR, FOXO1-WT, or FOXO1-3A were challenged with repeated tumor stimulation or at a low effector to tumor (E:T) ratio. After 3 tumor challenges, CD19.BBz CAR-T cells were allowed to rest for 7 days before phenotyping to determine the extent to which FOXO1-engineered CAR-T cells could form memory, an important feature for maintaining anti-tumor responses. Compared with TCF1 or NGFR cells, cells expressing FOXO1-WT and FOXO1-3A maintained higher expression levels of the memory markers CD62L and IL-7R, suggesting that they have an enhanced ability to form and / or persist memory ( Fig. 8A ). For both CD19.28z and CD19.BBz CAR-T cells, ectopic FOXO1-WT (but paradoxically, FOXO1-3A not) enhanced FOXO1 killing compared with NGFR controls ( Figures 8B-8C ). Further exploration revealed that FOXO1-WT CAR-T cells exhibited enhanced CAR-T cell expansion at low E:T ratios compared with NGFR and FOXO1-3A ( Fig.8DThese data suggest that FOXO1-WT cells are more efficient than FOXO1-3A and NGFR cells in the setting of chronic antigen stimulation and that the fixed nuclear localization of FOXO1-3A limits CAR-T cell expansion or effector function during chronic stimulation.
[0155] Example 7
[0156] Ectopic FOXO1 alleviates T cell exhaustion
[0157] The enhancement of CAR-T cell function by ectopic TF expression was also tested in a validated in vitro model of CAR-T cell exhaustion, in which a high-affinity GD2-targeting CAR (HA.28z) promoted antigen-independent aggregation and signaling, as well as the rapid onset of T cell dysfunction. Both FOXO1-WT and FOXO1-3A-expressing HA.28z CAR-T cells exhibited an altered surface phenotype, in which exhaustion markers such as CD39 and PD-1 were reduced, while memory markers and FOXO1 target genes such as CD62L were increased ( Figures 9A-9B ). FOXO1-WT cells exhibited enhanced cytokine secretion and killing compared with controls; however, although FOXO1-3A cells displayed a surface phenotype consistent with non-depleted cells ( Figures 9C-9E ), but their function was not enhanced, which is consistent with the observation of CD19-targeted CARs that received chronic stimulation (Figure 8). Together, these data suggest that ectopic FOXO1-WT can counteract CAR-T cell exhaustion and enhance its function.
[0158] Example 8
[0159] Constitutive expression of FOXO1 confers depletion resistance
[0160] To test whether constitutive FOXO1-WT alleviates depletion in the HA.28z CAR model or whether transient expression upon tumor exposure is sufficient to enhance function, the destabilizing domain was fused to the N-terminus of FOXO1-WT (DD-FOXO1-WT), allowing precise, drug-dependent expression control ( Fig. 10A HA.28zCAR-T cells expressing DD-FOXO1-WT from day 4 to day 15 showed increased IL-2 secretion in response to tumors, whereas HA.28z CAR-T cells expressing DD-FOXO1-WT starting 24 hours before tumor attack did not show this phenomenon ( Fig. 10B ).
[0161] Example 9
[0162] Ectopic FOXO1 metabolically reprograms CAR-T cells
[0163] Since FOXO1 promotes memory and stemness in CAR-T cells, and these phenotypes are known to be associated with differential metabolic signatures compared with effector T cells, we speculated that ectopic FOXO1 may be driving metabolic reprogramming in CAR-T cells. Using the Seahorse assay, we found that both FOXO1-WT and FOXO1-3A reduced the extracellular acidification rate (basal ECAR) and increased mitochondrial fitness (e.g., spare respiratory capacity, SRC) in both resting CD19-targeted cells and exhausted HA.28z CAR-T cells ( Fig.11A FOXO1-WT and FOXO1-3A CAR-T cells also exhibited higher mitochondrial mass than NGFR controls in the unstimulated state ( Fig. 11B Antigen stimulation further increased mitochondrial mass in FOXO1-engineered CAR-T cells, whereas NGFR control cells remained at baseline levels ( Fig. 11C Together, these data demonstrate that ectopic FOXO1-WT and FOXO1-3A metabolically reprogram CAR-T cells to have features of memory T cells.
[0164] Example 10
[0165] FOXO1-engineered CAR-T cells mediate enhanced tumor control and mouse survival in a liquid tumor model
[0166] Non-curative doses of TF-engineered or control CAR-T cells (CD19.28z, CD19.BBz, or HA.28z) were infused into mice transplanted with Nalm6 leukemia. FOXO1-WT and CAR-T cells showed significantly enhanced tumor control and survival compared with NGFR control and TCF1 cells ( Figures 12A-12C , 21). FOXO1-3A CAR-T cells also exhibited enhanced tumor control and survival compared with NGFR control and TCF1 cells, but to a lesser extent than FOXO1-WT and CAR-T cells. These data further support the notion that ectopic FOXO1 enhances CAR-T cell function by alleviating T cell exhaustion and enhancing the stemness program, particularly in the setting of chronic antigen exposure. Finally, FOXO1-WT HA.28z CAR-T cells functionally outperformed NGFR control cells in vitro and exhibited enhanced tumor control in a leukemia xenograft model in which Nalm6 leukemia cells were engineered to express GD2 ( Fig.12D ).
[0167] Embodiment 11
[0168] CAR-T cells expressing FOXO1-WT outperform FOXO1-3A via enhanced expansion, persistence, and recall in an in vivo leukemia model
[0169] Curative doses of NGFR-purified CD19.28z CAR T cells (co-expressing ectopic FOXO1-WT, FOXO1-3A, TCF1, or control NGFR) were infused into NSG mice transplanted with Nalm6 leukemia. Circulating levels of CAR-T cells were measured 7 days after CAR-T infusion and every 7 days thereafter ( Fig.13A ). All groups had tumor clearance one week later ( Fig. 13B ), mice were challenged again with a high dose of 10e6Nalm6 to assess whether the persisting CAR-T cells responded to the secondary challenge. The circulating CAR-T cells detected at each time point remained CAR+ / NGFR+( Fig. 13C ), and the CAR surface density remained consistent across experimental groups ( Fig.13D Notably, at day 7 after infusion, FOXO1-WT cells expanded approximately 28-fold compared to NGFR controls and 20-fold compared to FOXO1-3A cells ( Figures 14A-14B FOXO1-3A cells exhibited robust but delayed expansion, as circulating levels peaked at day 14 post-infusion, far exceeding NGFR control levels but still 1 / 4–1 / 5 of the FOXO1-WT levels observed at day 7 ( Figures 14A-14B FOXO1-WT and FOXO1-3A CAR-T cells showed equivalent persistence in mice for up to 21 days, while control NGFR and TCF1 cells were barely detectable at this time point ( Figures 14A-14B). Seven days after tumor re-challenge (day 28), only FOXO1-WT cells showed recall ability, characterized by circulating CAR-T cells that responded to re-challenge and expanded 2-3 times, and prolonged mouse survival (Figure 14). In contrast, circulating FOXO1-3A CAR-T cell levels continued to decline after re-challenge, and eventually these mice and mice treated with control NGFR and TCF1 cells died of disease (Figure 14). Importantly, at all time points, the relative frequency of CD8 CAR-T cells under FOXO1-WT and FOXO1-3A conditions was significantly higher compared to controls, indicating that FOXO1 plays a role in enhancing CD8+CAR-T cell expansion and persistence (Figure 15). In summary, FOXO1-WT and FOXO1-3A CAR-T cells showed enhanced expansion and persistence compared to control NGFR and TCF1 cells. However, FOXO1-WT cells expanded more robustly and retained their antitumor function compared with FOXO1-3A cells, further supporting the notion that ectopic FOXO1-WT enhances CAR-T cell function to a greater extent than ectopic FOXO1-3A.
[0170] Example 12
[0171] FOXO1-engineered CAR-T cells enhance CAR-T cell targeting of solid tumors
[0172] Compared with CD19-targeted CAR-T cells, FOXO1-engineered cells had similar phenotype and function to control CAR-T cells at rest and during transient activation, whereas ectopic FOXO1-WT targeting Her2 (Her2.28z and Her2.BBz) exhibited higher frequencies of memory-like T cells at rest and enhanced function in short-term assays ( Figures 16A-16C ). A non-purified dose of 10e6 CAR-T cells, of which only 50% were NGFR / FOXO1-WT+, was infused into mice transplanted with the osteosarcoma cell line 143B. FOXO1-WT cells enhanced tumor control in this extremely aggressive solid tumor model ( Figures 16D-16E ), indicating that this approach has broad application in solid tumors in addition to hematological malignancies.
[0173] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference was individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[0174] Preferred embodiments of the present invention are described herein, including the best mode known to the inventor for carrying out the present invention. After reading the foregoing description, changes to those preferred embodiments will be apparent to those of ordinary skill in the art. The inventor expects that skilled technicians will appropriately adopt such changes, and the inventor intends to implement the present invention in a manner different from that specifically described herein. Therefore, the present invention includes all modifications and equivalents of the subject matter described in the appended claims as permitted by applicable law. In addition, unless otherwise specified herein or clearly contradictory to the context, the present invention encompasses any combination of the above-mentioned elements in all possible variations thereof.
Claims
1. A composition comprising isolated T cells comprising exogenous nucleic acid encoding forkhead box protein O1 (FOXO1).
2. The composition according to claim 1, wherein The FOXO1 is constitutively expressed by the exogenous nucleic acid.
3. The composition according to claim 1 or 2, wherein The FOXO1 is fused with motifs that modulate expression levels or enhance intracellular degradation.
4. The composition according to any one of claims 1 to 3, wherein The isolated T cells remain functional under conditions in which unmodified T cells exhibit exhaustion.
5. The composition according to any one of claims 1 to 4, wherein The isolated T cell further comprises a nucleic acid encoding the recombinant receptor.
6. The composition according to claim 5, wherein The recombinant receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR).
7. The composition according to claim 5 or 6, wherein The recombinant receptor is specific for tumor antigens.
8. A composition according to any one of claims 5 to 7, wherein The FOXO1 and engineered receptor are encoded by separate nucleic acids.
9. The composition according to any one of claims 5 to 7, wherein The FOXO1 and the engineered receptor are encoded by a single nucleic acid.
10. The composition according to any one of claims 5 to 9, wherein The FOXO1 and engineered receptor were expressed under different promoters.
11. The composition according to any one of claims 1 to 10, wherein The isolated T cells are from a biological sample of a subject.
12. The composition according to any one of claims 1 to 11, wherein The isolated T cells are isolated from a tumor sample.
13. The composition according to any one of claims 1 to 12, wherein The isolated T cells are expanded ex vivo.
14. The composition of any one of claims 1-13, further comprising at least one therapeutic agent.
15. A method of treating a disease or disorder in a subject, the method comprising administering to a subject suffering from the disease or disorder an effective amount of the composition of any one of claims 1-14.
16. The method according to claim 15, wherein: The isolated T cells are autologous to the subject.
17. The method according to claim 15 or 16, wherein: FOXO1 is overexpressed in the isolated T cells before exposure to antigen.
18. The method according to any one of claims 15 to 17, wherein: The disease or condition includes an infectious disease or cancer.
19. The method according to claim 18, wherein: The cancer is a solid tumor.
20. The method according to any one of claims 18 or 19, wherein: The recombinant receptor is specific for the cancer.
21. The method according to any one of claims 18 to 20, wherein: The administration reduces the number of cancer cells in the patient.
22. The method according to any one of claims 18 to 21, wherein: Said administration reduces and / or eliminates tumor burden in said patient.
23. The method according to any one of claims 18 to 22, wherein: Such administration showed enhanced cancer treatment compared to administration of unmodified T cells.
24. The method of any one of claims 18-23, further comprising administering one or more chemotherapeutic agents to the patient.
25. The method according to any one of claims 15 to 24, wherein: The administration results in lower expression of inhibitory receptors in the subject compared to administration of unmodified T cells.
26. A method for preventing exhaustion of engineered T cells, the method comprising introducing a nucleic acid that overexpresses FOXO1 into the engineered T cells.
27. The method according to claim 26, wherein: The FOXO1 is wild-type FOXO1 or a functional fragment or variant thereof.
28. The method according to claim 26 or 27, wherein: The nucleic acid promotes constitutive expression of FOXO1 from the nucleic acid.
29. The method according to any one of claims 26 to 28, wherein: The engineered T cell further comprises a nucleic acid encoding the recombinant receptor.
30. The method of claim 29, wherein: The recombinant receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR).
31. The method according to claim 29 or 30, wherein: The recombinant receptor is specific for tumor antigens.
32. The method according to claim 31, wherein: The FOXO1 is overexpressed prior to exposure to the antigen.
33. The method according to any one of claims 29 to 32, wherein: The FOXO1 and engineered receptor are encoded by separate nucleic acids.
34. The method according to any one of claims 29 to 32, wherein: The FOXO1 and the engineered receptor are encoded by a single nucleic acid.
35. The method according to any one of claims 29 to 34, wherein: The FOXO1 and engineered receptor were expressed under different promoters.
36. The method of any one of claims 26-35, further comprising administering the T cells to a subject in need thereof.
37. The method of claim 36, wherein: The subject suffers from cancer.
38. Use of a composition according to any one of claims 1-14 for treating a disease or disorder in a subject.
39. Use of an exogenous nucleic acid configured to overexpress FOXO1 for preventing exhaustion of engineered T cells.
